CDSCO Panel Asks Astellas Pharma to Update Enzalutamide Label After Phase IV Study

Published On 2025-09-24 11:57 GMT | Update On 2025-09-24 11:57 GMT

New Delhi: The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO), has opined Astellas Pharma India to update the prescribing information of Enzalutamide 40 mg soft capsule after reviewing the results of a Phase IV clinical study.

This came after Astellas Pharma India presented Phase IV clinical trial report of Enzalutamide 40 mg soft Capsule along with the Serious Adverse Event (SAEs) reported, before the committee.

Firm presented study objective, study design, study endpoints, Inclusion and Exclusion criteria, safety assessment, demographic & baseline characteristics, study population, efficacy results, safety results TEAEs reported during study, Drug related Serious Treatment-Emergent Adverse Events (TEAEs) etc.

Also Read: Sun Pharma Gets CDSCO Panel Nod to Manufacture, Market Enzalutamide for Prostate Cancer

Enzalutamide is a competitive androgen receptor (AR) inhibitor that has a threefold inhibition on the androgen signaling pathway without significant AR agonist activity. It inhibits androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with chromosomal DNA to upregulate oncogenes. Enzalutamide binds to the AR with 5- to 8-fold greater affinity than first-generation antiandrogens such as bicalutamide and only 2- to 3-fold reduced affinity than the natural ligand dihydrotestosterone.

After detailed deliberation, the committee considered the results of the Phase IV clinical study and recommended that the firm should update the phase IV study and SAEs outcome in the prescribing information and the revised prescribing information should be submitted to CDSCO within one month for further review by the committee.

Also Read: Intas Pharma gest CDSCO panel nod to manufacture, market anticancer drug Enzalutamide tablet

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Panel Asks Astellas Pharma to Update Enzalutamide Label After Phase IV Study

Similar News

Intas Pharma Told to Revise Phase I, III Pembrolizumab Trial Protocol

CDSCO Panel Asks Akums for Detailed Data on Phase III Eye Drop Trial

CDSCO Panel Flags Trial Death, Seeks Causality Report from Reliance Life Sciences on EtanerRel

Spurious Drugs Alert: Diazepam, PAN 40, and PAN-D Capsules Under Investigation

Biocon Gets CDSCO Panel Nod to Import Aflibercept Injection for Eye Disorders, Phase IV Trial Mandated

94 Drug, Medical Product Batches Fail CDSCO Quality Tests in August

Sun Pharma Told to Limit Phase III Revefenacin Study to Triple Therapy COPD Patients